Stockscreener 앱 받기
6.97
3.73%
-0.27
시간 외 거래:
6.99
0.02
+0.29%
전일 마감가:
$7.24
열려 있는:
$7.07
하루 거래량:
32,117
Relative Volume:
0.55
시가총액:
$16.30M
수익:
-
순이익/손실:
$-14.39M
주가수익비율:
-0.8697
EPS:
-8.0144
순현금흐름:
$-11.83M
1주 성능:
-2.92%
1개월 성능:
+12.24%
6개월 성능:
-47.08%
1년 성능:
-64.29%
1일 변동 폭
$6.83
$7.22
1주일 범위
$6.83
$7.9233
52주 변동 폭
$4.91
$20.00
Cadrenal Therapeutics Inc Stock (CVKD) Company Profile
명칭
Cadrenal Therapeutics Inc
전화
904-300-0701
주소
822 A1A NORTH, PONTE VEDRA
Compare CVKD vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CVKD
Cadrenal Therapeutics Inc
|
6.97 | 16.93M | 0 | -14.39M | -11.83M | -8.0144 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cadrenal Therapeutics Inc Stock (CVKD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-12-18 | 개시 | Noble Capital Markets | Outperform |
Cadrenal Therapeutics Inc 주식(CVKD)의 최신 뉴스
Trading Action: Is Cadrenal Therapeutics Inc stock overvalued or fairly pricedEarnings Overview Summary & Verified Short-Term Plans - baoquankhu1.vn
Cadrenal Therapeutics Highlights CAD-1005 In-License, Maps Phase III Path for HIT at Investor Forum - Defense World
CVKD SEC FilingsCadrenal Therape 10-K, 10-Q, 8-K Forms - Stock Titan
Cadrenal Therapeutics, Inc. (CVKD) stock: surges on breakthrough 12-LOX diabetes research - parameter.io
Cadrenal Therapeutics Inc. (CVKD) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Trading the Move, Not the Narrative: (CVKD) Edition - Stock Traders Daily
Cadrenal Therapeutics Highlights Research Supporting 12-LOX Inhibition in Reducing Inflammation in Obesity and Type 2 Diabetes - Sahm
CVKD: CAD-1005 moves to phase III for HIT, aiming to address a critical unmet need with strong safety data - TradingView
CVKD: CAD-1005 advances to phase III for HIT, targeting a major unmet need with strong regulatory support - TradingView
Cadrenal Highlights CAD-1005 Preclinical Data in Metabolic Disease - TipRanks
Cadrenal Therapeutics (CVKD) spotlights CAD-1005 12-LOX data in obesity, diabetes and HIT - Stock Titan
Trend Recap: What is Cadrenal Therapeutics Incs valuation compared to sector2026 Top Gainers & Expert-Curated Trade Recommendations - baoquankhu1.vn
Cadrenal Therapeutics Inc expected to post a loss of $1.16 a shareEarnings Preview - TradingView
CVKD Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
CVKD Stock Price, Quote & Chart | CADRENAL THERAPEUTICS INC (NASDAQ:CVKD) - ChartMill
Cadrenal Therapeutics (CVKD) Projected to Post Quarterly Earnings on Thursday - Defense World
CVKDCadrenal Therapeutics Highlights Recent 12-LOX Inhibitor Platform Expansion - ADVFN Ltd
Cadrenal schedules FDA meeting for HIT drug CAD-1005 - Investing.com India
Cadrenal Therapeutics Highlights Recent 12-LOX Inhibitor Platform Expansion - GlobeNewswire
(CVKD) Volatility Zones as Tactical Triggers - Stock Traders Daily
Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Short Interest Update - Defense World
Cadrenal Therapeutics, Inc. Common Stock (CVKD) Stock Forecast & Price Prediction 2026–2030 - CoinCodex
CVKD Should I Buy - Intellectia AI
Cadrenal’s CAD-1005 shows reduction in blood clots in HIT trial - Investing.com India
CVKD: Phase 2 HIT Results Show Encouraging Reduction in Thrombotic Events - Yahoo Finance
Cadrenal’s CAD-1005 shows reduction in blood clots in HIT trial By Investing.com - Investing.com Canada
Cadrenal Therapeutics stock surges on Phase 2 trial results - Investing.com South Africa
Cadrenal Therapeutics' recent acquisition makes progress toward phase 3 trial - The Business Journals
Cadrenal Therapeutics stock surges on Phase 2 trial results By Investing.com - Investing.com Nigeria
Cadrenal Highlights Mixed Phase 2 Results for CAD-1005 - TipRanks
Cadrenal Therapeutics Inc recently received approval from the U.S. Food and Drug Administration (FDA) to hold an end-of-Phase II clinical trial meeting. - Bitget
Cadrenal Therapeutics announces phase 2 results for CAD-1005 - marketscreener.com
Cadrenal Therapeutics Reports Over 25% Reduction in Thrombotic Events with CAD-1005 in Phase 2 Trial for Heparin-Induced Thrombocytopenia - Quiver Quantitative
Cadrenal Therapeutics Announces Phase 2 Results with Encouraging Reductions in Thrombotic Events for CAD-1005 in HIT, Supporting Clinical Advancement - Bitget
Cadrenal Therapeutics reports Phase 2: CAD-1005 cuts thrombotic events >25% vs placebo; EOP2 meeting set - TradingView
CAD-1005 Phase 2 data spur FDA EOP2 talks for Cadrenal (NASDAQ: CVKD) - Stock Titan
Cadrenal Therapeutics Announces Phase 2 Results For CAD-1005 - TradingView
Cadrenal Therapeutics Announces Phase 2 Results with - GlobeNewswire
Smart Money: What is Cadrenal Therapeutics Incs valuation compared to sector2025 Support & Resistance & Risk Controlled Daily Trade Plans - baoquankhu1.vn
Cadrenal Therapeutics expands at-the-market stock offering capacity - MSN
What is Cadrenal Therapeutics Inc. s revenue forecastJuly 2025 Action & Free Fast Entry Momentum Trade Alerts - mfd.ru
Trading Recap: Can Cadrenal Therapeutics Inc. stock double in the next yearDollar Strength & Daily Growth Stock Investment Tips - mfd.ru
CVKD: Acquires 12-LOX Inhibitor for the Treatment of Heparin-Induced Thrombocytopenia (HIT) - Yahoo Finance
Cadrenal Therapeutics to Engage Potential Partners at BIO International Convention 2025 - Intellectia AI
Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Short Interest Up 22.1% in January - Defense World
Can Cadrenal Therapeutics Inc. weather a recessionJuly 2025 Selloffs & Weekly Chart Analysis and Guides - mfd.ru
Is Cadrenal Therapeutics Inc. stock a safe haven assetWeekly Trend Report & Smart Allocation Stock Tips - mfd.ru
Fed Meeting: Can Cadrenal Therapeutics Inc stock double in the next yearIndex Update & Free Safe Capital Growth Stock Tips - baoquankhu1.vn
Cadrenal Therapeutics (NASDAQ:CVKD) Shares Up 0.4% – What’s Next? - Defense World
(CVKD) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Profit Review: Will Cadrenal Therapeutics Inc outperform its industry peersMarket Risk Analysis & Daily Risk Controlled Trade Plans - baoquankhu1.vn
Cadrenal Therapeutics Inc (CVKD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):